Pulmonary hypertension (PH) due to left heart disease, classified as group 2 according to the Dana Point 2008 classification, is believed to be the most common cause of PH and is associated with high morbidity and mortality. PH secondary to left ventricular systolic dysfunction (LVSD) is present in approximately 68% to 78% of patients with advanced heart failure (HF) and concomitant right ventricular (RV) dysfunction. Other than phosphodiesterase inhibitors, there is no effective treatment of PH.

Utilizing our patented NO technology, current trials at Texas Heart Institute reveal that NO can dilate pulmonary vasculature and lead to a reduction in pulmonary pressures within 20 minutes.